{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:38:22Z","timestamp":1793410702833,"version":"4.5.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41575-024-00955-8","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T07:03:16Z","timestamp":1721199796000},"page":"809-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A roadmap for clinical trials in MASH-related compensated cirrhosis"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-3293","authenticated-orcid":false,"given":"Juan M.","family":"Peric\u00e0s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-0088","authenticated-orcid":false,"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1119-7799","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-9016","authenticated-orcid":false,"given":"Annalisa","family":"Berzigotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Ciudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7527-4714","authenticated-orcid":false,"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan G.","family":"Abraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hern\u00e1ndez-Gea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f2nica","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-3583","authenticated-orcid":false,"given":"Thomas","family":"Reiberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1288-0749","authenticated-orcid":false,"given":"Ian A.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rydqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmer","family":"Schabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5069-2461","authenticated-orcid":false,"given":"Emmanuel A.","family":"Tsochatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0831-8422","authenticated-orcid":false,"given":"Joan","family":"Genesc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"955_CR1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"955_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.metabol.2015.11.008","volume":"65","author":"GT Brown","year":"2016","unstructured":"Brown, G. T. & Kleiner, D. E. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 65, 1080\u20131086 (2016).","journal-title":"Metabolism"},{"key":"955_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","volume":"16","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411\u2013428 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123\u2013133 (2018).","journal-title":"Hepatology"},{"key":"955_CR6","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes, C. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J. Hepatol. 69, 896\u2013904 (2018).","journal-title":"J. Hepatol."},{"key":"955_CR7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"955_CR8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q. et al. Global epidemiology of cirrhosis \u2014 aetiology, trends and predictions. Nat. Rev. Gastroenterol. Hepatol. 20, 388\u2013398 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223\u2013238 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","volume":"18","author":"S Francque","year":"2021","unstructured":"Francque, S. et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat. Rev. Gastroenterol. Hepatol. 18, 24\u201339 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","volume":"78","author":"JT Haas","year":"2016","unstructured":"Haas, J. T., Francque, S. & Staels, B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu. Rev. Physiol. 78, 181\u2013205 (2016).","journal-title":"Annu. Rev. Physiol."},{"key":"955_CR12","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s12325-019-00898-6","volume":"36","author":"S Francque","year":"2019","unstructured":"Francque, S. & Vonghia, L. Pharmacological treatment for non-alcoholic fatty liver disease. Adv. Ther. 36, 1052\u20131107 (2019).","journal-title":"Adv. Ther."},{"key":"955_CR13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","volume":"1","author":"S Lefere","year":"2019","unstructured":"Lefere, S. & Tacke, F. Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism. JHEP Rep. 1, 30\u201343 (2019).","journal-title":"JHEP Rep."},{"key":"955_CR14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"Gastaldelli, A. & Cusi, K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 1, 312\u2013328 (2019).","journal-title":"JHEP Rep."},{"key":"955_CR15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","volume":"10","author":"A Wree","year":"2013","unstructured":"Wree, A., Broderick, L., Canbay, A., Hoffman, H. M. & Feldstein, A. E. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627\u2013636 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR16","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","volume":"70","author":"A Cheung","year":"2019","unstructured":"Cheung, A. et al. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum. Hepatology 70, 1841\u20131855 (2019).","journal-title":"Hepatology"},{"key":"955_CR17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jhep.2019.04.019","volume":"71","author":"ME Rinella","year":"2019","unstructured":"Rinella, M. E., Tacke, F., Sanyal, A. J. & Anstee, Q. M. Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD. J. Hepatol. 71, 823\u2013833 (2019).","journal-title":"J. Hepatol."},{"key":"955_CR18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","volume":"76","author":"V Ratziu","year":"2022","unstructured":"Ratziu, V., Francque, S. & Sanyal, A. Breakthroughs in therapies for NASH and remaining challenges. J. Hepatol. 76, 1263\u20131278 (2022).","journal-title":"J. Hepatol."},{"key":"955_CR19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"955_CR20","unstructured":"FDA. FDA Approves First Treatment for Patients with Liver Scarring due to Fatty Liver Disease, March 14 2024 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (2024)."},{"key":"955_CR21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cld.2023.01.010","volume":"27","author":"S Francque","year":"2023","unstructured":"Francque, S. & Ratziu, V. Future treatment options and regimens for nonalcoholic fatty liver disease. Clin. Liver Dis. 27, 429\u2013444 (2023).","journal-title":"Clin. Liver Dis."},{"key":"955_CR22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi, K. et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pract. 28, 528\u2013562 (2022).","journal-title":"Endocr. Pract."},{"key":"955_CR23","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922 (2018).","journal-title":"Nat. Med."},{"key":"955_CR24","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal, A. J. et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N. Engl. J. Med. 385, 1559\u20131569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"955_CR25","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","volume":"77","author":"AM Allen","year":"2022","unstructured":"Allen, A. M. et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J. Hepatol. 77, 1237\u20131245 (2022).","journal-title":"J. Hepatol."},{"key":"955_CR26","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797\u20131835 (2023).","journal-title":"Hepatology"},{"key":"955_CR27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M., Zelber-Sagi, S., Henry, L. & Gerber, L. H. Lifestyle interventions in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 20, 708\u2013722 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR28","doi-asserted-by":"crossref","first-page":"E733","DOI":"10.1055\/a-1880-2388","volume":"60","author":"F Tacke","year":"2022","unstructured":"Tacke, F. et al. Updated S2k clinical practice guideline on non-alcoholic fatty liver disease (NAFLD) issued by the German Society of Gastroenterology, digestive and metabolic diseases (DGVS). Z. Gastroenterol. 60, E733\u2013E801 (2022).","journal-title":"Z. Gastroenterol."},{"key":"955_CR29","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.gie.2018.08.030","volume":"89","author":"L Fayad","year":"2019","unstructured":"Fayad, L. et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest. Endosc. 89, 782\u2013788 (2019).","journal-title":"Gastrointest. Endosc."},{"key":"955_CR30","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","volume":"326","author":"A Aminian","year":"2021","unstructured":"Aminian, A. et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 326, 2031\u20132042 (2021).","journal-title":"JAMA"},{"key":"955_CR31","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"955_CR32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"955_CR33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba, R. et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 511\u2013522 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"955_CR34","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro, O. et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 401, 1786\u20131797 (2023).","journal-title":"Lancet"},{"key":"955_CR35","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196 (2019).","journal-title":"Lancet"},{"key":"955_CR36","unstructured":"Sanyal, A. J. et al. Topline results from a new analysis of the regenerate trial of obeticholic acid for the treatment of nonalcoholic steatohepatitis. Abstract 5008. The Liver Meeting 2022: American Association for the Study of Liver Diseases (AASLD), Washington, D.C., USA (2022)."},{"key":"955_CR37","doi-asserted-by":"crossref","unstructured":"Harrison, S. A. et al. Primary data analyses of MAESTRO-NAFLD-1 a 52 week double blind placebo-controlled phase 3 clinical trial of resmetirom in patients with NAFLD. EASL LB005. J. Hepatol. 77 (2023).","DOI":"10.1016\/S0168-8278(22)00445-7"},{"key":"955_CR38","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","volume":"73","author":"S Lefere","year":"2020","unstructured":"Lefere, S. et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J. Hepatol. 73, 757\u2013770 (2020).","journal-title":"J. Hepatol."},{"key":"955_CR39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke, F., Puengel, T., Loomba, R. & Friedman, S. L. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J. Hepatol. 79, 552\u2013566 (2023).","journal-title":"J. Hepatol."},{"key":"955_CR40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","volume":"385","author":"SM Francque","year":"2021","unstructured":"Francque, S. M. et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N. Engl. J. Med. 385, 1547\u20131558 (2021).","journal-title":"N. Engl. J. Med."},{"key":"955_CR41","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison, S. A. et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat. Med. 27, 1262\u20131271 (2021).","journal-title":"Nat. Med."},{"key":"955_CR42","doi-asserted-by":"crossref","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","volume":"5","author":"SA Harrison","year":"2023","unstructured":"Harrison, S. A. et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep. 5, 100563 (2023).","journal-title":"JHEP Rep."},{"key":"955_CR43","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04767529 (2023)."},{"key":"955_CR44","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.3390\/ijms23126696","volume":"23","author":"T Puengel","year":"2022","unstructured":"Puengel, T. et al. Combined therapy with a CCR2\/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis. Int. J. Mol. Sci. 23, 6696 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"955_CR45","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri, N. et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J. Hepatol. 77, 607\u2013618 (2022).","journal-title":"J. Hepatol."},{"key":"955_CR46","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03439254 (2023)."},{"key":"955_CR47","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03053063 (2019)."},{"key":"955_CR48","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04365868 (2019)."},{"key":"955_CR49","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04849728?cond=steatohepatitis&intr=lanifibranor (2021)."},{"key":"955_CR50","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","volume":"74","author":"Z Boyer-Diaz","year":"2021","unstructured":"Boyer-Diaz, Z. et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J. Hepatol. 74, 1188\u20131199 (2021).","journal-title":"J. Hepatol."},{"key":"955_CR51","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04210245 (2019)."},{"key":"955_CR52","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04971785 (2021)."},{"key":"955_CR53","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04197479 (2019)."},{"key":"955_CR54","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05500222 (2022)."},{"key":"955_CR55","unstructured":"U.S. Food and Drug Administration. Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance For Industry https:\/\/www.fda.gov\/media\/127738\/download (2023)."},{"key":"955_CR56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez, E. et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology 155, 443\u2013457 (2018).","journal-title":"Gastroenterology"},{"key":"955_CR57","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/hep4.2056","volume":"6","author":"O Bassegoda","year":"2022","unstructured":"Bassegoda, O. et al. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: a retrospective cohort study. Hepatol. Commun. 6, 3212\u20133222 (2022).","journal-title":"Hepatol. Commun."},{"key":"955_CR58","unstructured":"The European Medicines Agency - EMA EMA\/CHMP\/299976\/2018. Reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-reflection-paper-regulatory-requirements-development-medicinal-products-chronic-non-infectious-liver-diseases-pbc-psc-nash_en.pdf (2018)."},{"key":"955_CR59","unstructured":"U.S. Food and Drug Administration. Regulatory Perspectives for Development of Drugs for Treatment of NASH https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/regulatory-perspectives-development-drugs-treatment-nash-01292021-01292021 (2021)."},{"key":"955_CR60","first-page":"365","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 365\u2013367 (2015).","journal-title":"Gastroenterology"},{"key":"955_CR61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat, K. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121\u2013129 (2010).","journal-title":"Hepatology"},{"key":"955_CR62","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","volume":"49","author":"SA Harrison","year":"2009","unstructured":"Harrison, S. A., Fecht, W., Brunt, E. M. & Neuschwander-Tetri, B. A. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 49, 80\u201386 (2009).","journal-title":"Hepatology"},{"key":"955_CR63","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","volume":"59","author":"VW Wong","year":"2013","unstructured":"Wong, V. W. et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J. Hepatol. 59, 536\u2013542 (2013).","journal-title":"J. Hepatol."},{"key":"955_CR64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1053\/j.gastro.2012.10.001","volume":"144","author":"A Berzigotti","year":"2013","unstructured":"Berzigotti, A. et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology 144, 102\u2013111 (2013).","journal-title":"Gastroenterology"},{"key":"955_CR65","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","volume":"65","author":"A Berzigotti","year":"2017","unstructured":"Berzigotti, A. et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology 65, 1293\u20131305 (2017).","journal-title":"Hepatology"},{"key":"955_CR66","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.mcna.2022.12.007","volume":"107","author":"C Bunchorntavakul","year":"2023","unstructured":"Bunchorntavakul, C. Sarcopenia and frailty in cirrhosis: assessment and management. Med. Clin. North Am. 107, 589\u2013604 (2023).","journal-title":"Med. Clin. North Am."},{"key":"955_CR67","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","volume":"18","author":"D Eisenberg","year":"2022","unstructured":"Eisenberg, D. et al. American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg. Obes. Relat. Dis. 18, 1345\u20131356 (2022).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"955_CR68","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2020","unstructured":"Newsome, P. N. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N. Engl. J. Med. 384, 1113\u20131124 (2020).","journal-title":"N. Engl. J. Med."},{"key":"955_CR69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679\u2013690 (2016).","journal-title":"Lancet"},{"key":"955_CR70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli, A. et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10, 393\u2013406 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"955_CR71","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04166773 (2019)."},{"key":"955_CR72","doi-asserted-by":"crossref","first-page":"735019","DOI":"10.3389\/fendo.2021.735019","volume":"12","author":"DCD Hope","year":"2021","unstructured":"Hope, D. C. D., Vincent, M. L. & Tan, T. M. M. Striking the balance: GLP-1\/glucagon co-agonism as a treatment strategy for obesity. Front. Endocrinol. 12, 735019 (2021).","journal-title":"Front. Endocrinol."},{"key":"955_CR73","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","volume":"2","author":"ML Boland","year":"2020","unstructured":"Boland, M. L. et al. Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis. Nat. Metab. 2, 413\u2013431 (2020).","journal-title":"Nat. Metab."},{"key":"955_CR74","volume":"384","author":"KH Lewis","year":"2024","unstructured":"Lewis, K. H., Sloan, C. E., Bessesen, D. H. & Arterburn, D. Effectiveness and safety of drugs for obesity. BMJ 384, e072686 (2024).","journal-title":"BMJ"},{"key":"955_CR75","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14111","volume":"7","author":"I Casimiro","year":"2019","unstructured":"Casimiro, I., Sam, S. & Brady, M. J. Endocrine implications of bariatric surgery: a review on the intersection between incretins, bone, and sex hormones. Physiol. Rep. 7, e14111 (2019).","journal-title":"Physiol. Rep."},{"key":"955_CR76","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly, G. et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 159, 1290\u20131301 (2020).","journal-title":"Gastroenterology"},{"key":"955_CR77","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S2213-8587(19)30191-3","volume":"7","author":"J Thereaux","year":"2019","unstructured":"Thereaux, J. et al. Long-term adverse events after sleeve gastrectomy or gastric bypass: a 7-year nationwide, observational, population-based, cohort study. Lancet Diabetes Endocrinol. 7, 786\u2013795 (2019).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"955_CR78","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/bjs.10258","volume":"103","author":"O Backman","year":"2016","unstructured":"Backman, O., Stockeld, D., Rasmussen, F., N\u00e4slund, E. & Marsk, R. Alcohol and substance abuse, depression and suicide attempts after Roux-en-Y gastric bypass surgery. Br. J. Surg. 103, 1336\u20131342 (2016).","journal-title":"Br. J. Surg."},{"key":"955_CR79","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","volume":"17","author":"Y Lee","year":"2019","unstructured":"Lee, Y. et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 17, 1040\u20131060.e11 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR80","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s11695-022-06011-1","volume":"32","author":"H Zhou","year":"2022","unstructured":"Zhou, H. et al. Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis. Obes. Surg. 32, 1872\u20131883 (2022).","journal-title":"Obes. Surg."},{"key":"955_CR81","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.soard.2022.12.025","volume":"19","author":"G Wang","year":"2023","unstructured":"Wang, G. et al. Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis. Surg. Obes. Relat. Dis. 19, 717\u2013726 (2023).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"955_CR82","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s11695-021-05237-9","volume":"31","author":"YP Mendoza","year":"2021","unstructured":"Mendoza, Y. P. et al. Malnutrition and alcohol in patients presenting with severe complications of cirrhosis after laparoscopic bariatric surgery. Obes. Surg. 31, 2817\u20132822 (2021).","journal-title":"Obes. Surg."},{"key":"955_CR83","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s11695-015-1727-2","volume":"25","author":"A Jan","year":"2015","unstructured":"Jan, A., Narwaria, M. & Mahawar, K. K. A systematic review of bariatric surgery in patients with liver cirrhosis. Obes. Surg. 25, 1518\u20131526 (2015).","journal-title":"Obes. Surg."},{"key":"955_CR84","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.soard.2017.10.002","volume":"14","author":"Z Nor Hanipah","year":"2018","unstructured":"Nor Hanipah, Z. et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg. Obes. Relat. Dis. 14, 93\u201398 (2018).","journal-title":"Surg. Obes. Relat. Dis."},{"key":"955_CR85","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s11695-021-05289-x","volume":"31","author":"S Ahmed","year":"2021","unstructured":"Ahmed, S. et al. Outcomes of bariatric surgery in patients with liver cirrhosis: a systematic review. Obes. Surg. 31, 2255\u20132267 (2021).","journal-title":"Obes. Surg."},{"key":"955_CR86","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/lt.24832","volume":"23","author":"M Safwan","year":"2017","unstructured":"Safwan, M., Collins, K. M., Abouljoud, M. S. & Salgia, R. Outcome of liver transplantation in patients with prior bariatric surgery. Liver Transpl. 23, 1415\u20131421 (2017).","journal-title":"Liver Transpl."},{"key":"955_CR87","doi-asserted-by":"crossref","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner, D. E. et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. Open 2, e1912565\u2013e1912565 (2019).","journal-title":"JAMA Netw. Open"},{"key":"955_CR88","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","volume":"75","author":"AJ Sanyal","year":"2022","unstructured":"Sanyal, A. J. et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology 75, 1235\u20131246 (2022).","journal-title":"Hepatology"},{"key":"955_CR89","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jhep.2022.01.011","volume":"76","author":"EM Brunt","year":"2022","unstructured":"Brunt, E. M. et al. Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD. J. Hepatol. 76, 1030\u20131041 (2022).","journal-title":"J. Hepatol."},{"key":"955_CR90","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"BA Davison","year":"2020","unstructured":"Davison, B. A. et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J. Hepatol. 73, 1322\u20131332 (2020).","journal-title":"J. Hepatol."},{"key":"955_CR91","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cgh.2021.05.059","volume":"20","author":"IA Rowe","year":"2022","unstructured":"Rowe, I. A. & Parker, R. The placebo response in randomized trials in nonalcoholic steatohepatitis simply explained. Clin. Gastroenterol. Hepatol. 20, e564\u2013e572 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41575-023-00843-7","volume":"21","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J., Prakash, J. & Kleiner, D. E. Digital pathology for nonalcoholic steatohepatitis assessment. Nat. Rev. Gastroenterol. Hepatol. 21, 57\u201369 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR93","doi-asserted-by":"crossref","first-page":"732929","DOI":"10.3389\/fphys.2021.732929","volume":"12","author":"RP Cunningham","year":"2021","unstructured":"Cunningham, R. P. & Porat-Shliom, N. Liver zonation \u2014 revisiting old questions with new technologies. Front. Physiol. 12, 732929 (2021).","journal-title":"Front. Physiol."},{"key":"955_CR94","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/liv.15025","volume":"41","author":"JB Steinman","year":"2021","unstructured":"Steinman, J. B., Salomao, M. A. & Pajvani, U. B. Zonation in NASH \u2014 a key paradigm for understanding pathophysiology and clinical outcomes. Liver Int. 41, 2534\u20132546 (2021).","journal-title":"Liver Int."},{"key":"955_CR95","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.pathol.2022.01.009","volume":"54","author":"S Dhingra","year":"2022","unstructured":"Dhingra, S., Mahadik, J. D., Tarabishy, Y., May, S. B. & Vierling, J. M. Prevalence and clinical significance of portal inflammation, portal plasma cells, interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis. Pathology 54, 686\u2013693 (2022).","journal-title":"Pathology"},{"key":"955_CR96","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jhep.2022.08.028","volume":"77","author":"EK Mitten","year":"2022","unstructured":"Mitten, E. K. & Baffy, G. Mechanotransduction in the pathogenesis of non-alcoholic fatty liver disease. J. Hepatol. 77, 1642\u20131656 (2022).","journal-title":"J. Hepatol."},{"key":"955_CR97","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/gutjnl-2022-327498","volume":"72","author":"G Angelini","year":"2023","unstructured":"Angelini, G. et al. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis. Gut 72, 392\u2013403 (2023).","journal-title":"Gut"},{"key":"955_CR98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s12551-022-01041-6","volume":"15","author":"A Aghigh","year":"2023","unstructured":"Aghigh, A. et al. Second harmonic generation microscopy: a powerful tool for bio-imaging. Biophys. Rev. 15, 43\u201370 (2023).","journal-title":"Biophys. Rev."},{"key":"955_CR99","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/hep.30986","volume":"71","author":"F Liu","year":"2020","unstructured":"Liu, F. et al. qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis. Hepatology 71, 1953\u20131966 (2020).","journal-title":"Hepatology"},{"key":"955_CR100","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.cgh.2019.12.025","volume":"18","author":"R Forlano","year":"2020","unstructured":"Forlano, R. et al. High-throughput, machine learning-based quantification of steatosis, inflammation, ballooning, and fibrosis in biopsies from patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 18, 2081\u20132090.e9 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR101","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.31750","volume":"74","author":"A Taylor-Weiner","year":"2021","unstructured":"Taylor-Weiner, A. et al. A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH. Hepatology 74, 133\u2013147 (2021).","journal-title":"Hepatology"},{"key":"955_CR102","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","volume":"133","author":"C Ripoll","year":"2007","unstructured":"Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133, 481\u2013488 (2007).","journal-title":"Gastroenterology"},{"key":"955_CR103","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","volume":"68","author":"G D\u2019Amico","year":"2018","unstructured":"D\u2019Amico, G. et al. Clinical states of cirrhosis and competing risks. J. Hepatol. 68, 563\u2013576 (2018).","journal-title":"J. Hepatol."},{"key":"955_CR104","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.28031","volume":"62","author":"G Silva-Junior","year":"2015","unstructured":"Silva-Junior, G. et al. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology 62, 1584\u20131592 (2015).","journal-title":"Hepatology"},{"key":"955_CR105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/ajg.2011.456","volume":"107","author":"V Hern\u00e1ndez-Gea","year":"2012","unstructured":"Hern\u00e1ndez-Gea, V. et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with \u03b2-blockers. Am. J. Gastroenterol. 107, 418\u2013427 (2012).","journal-title":"Am. J. Gastroenterol."},{"key":"955_CR106","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","volume":"393","author":"C Villanueva","year":"2019","unstructured":"Villanueva, C. et al. \u03b2-Blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 393, 1597\u20131608 (2019).","journal-title":"Lancet"},{"key":"955_CR107","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","volume":"37","author":"JG Abraldes","year":"2003","unstructured":"Abraldes, J. G. et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37, 902\u2013908 (2003).","journal-title":"Hepatology"},{"key":"955_CR108","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/j.gastro.2017.01.011","volume":"152","author":"G Silva-Junior","year":"2017","unstructured":"Silva-Junior, G. et al. Timing affects measurement of portal pressure gradient after placement of transjugular intrahepatic portosystemic shunts in patients with portal hypertension. Gastroenterology 152, 1358\u20131365 (2017).","journal-title":"Gastroenterology"},{"key":"955_CR109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128774","volume":"10","author":"G Sebastiani","year":"2015","unstructured":"Sebastiani, G. et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS One 10, e0128774 (2015).","journal-title":"PLoS One"},{"key":"955_CR110","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.cgh.2018.12.038","volume":"17","author":"SG Rodrigues","year":"2019","unstructured":"Rodrigues, S. G. et al. Patients with signs of advanced liver disease and clinically significant portal hypertension do not necessarily have cirrhosis. Clin. Gastroenterol. Hepatol. 17, 2101\u20132109.e1 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR111","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","volume":"158","author":"N Chalasani","year":"2020","unstructured":"Chalasani, N. et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology 158, 1334\u20131345 (2020).","journal-title":"Gastroenterology"},{"key":"955_CR112","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","volume":"155","author":"SA Harrison","year":"2018","unstructured":"Harrison, S. A. et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 155, 1140\u20131153 (2018).","journal-title":"Gastroenterology"},{"key":"955_CR113","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","volume":"70","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal, A. J. et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology 70, 1913\u20131927 (2019).","journal-title":"Hepatology"},{"key":"955_CR114","volume":"61","author":"R Paternostro","year":"2023","unstructured":"Paternostro, R. et al. Natural history of patients with NAFLD-associated compensated advanced chronic liver disease stratified according to severity of portal hypertension. Z. Gastroenterol. 61, e195 (2023).","journal-title":"Z. Gastroenterol."},{"key":"955_CR115","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.cgh.2021.10.023","volume":"20","author":"O Bassegoda","year":"2022","unstructured":"Bassegoda, O. et al. Decompensation in advanced nonalcoholic fatty liver disease may occur at lower hepatic venous pressure gradient levels than in patients with viral disease. Clin. Gastroenterol. Hepatol. 20, 2276\u20132286.e6 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR116","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jhep.2020.10.003","volume":"74","author":"J Ferrusqu\u00eda-Acosta","year":"2021","unstructured":"Ferrusqu\u00eda-Acosta, J. et al. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. J. Hepatol. 74, 811\u2013818 (2021).","journal-title":"J. Hepatol."},{"key":"955_CR117","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.dld.2021.09.009","volume":"54","author":"R Paternostro","year":"2022","unstructured":"Paternostro, R. et al. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig. Liver Dis. 54, 500\u2013508 (2022).","journal-title":"Dig. Liver Dis."},{"key":"955_CR118","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource (FDA & NIH, 2016)."},{"key":"955_CR119","unstructured":"U.S. Food and Drug Administration. Considerations for Discussion of a New Surrogate Endpoint(s) at a Type C PDUFA Meeting Request https:\/\/www.fda.gov\/media\/115120\/download (2023)."},{"key":"955_CR120","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/hep.30842","volume":"70","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M. et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology 70, 1521\u20131530 (2019).","journal-title":"Hepatology"},{"key":"955_CR121","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali, Y. et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol. Hepatol. 8, 714\u2013725 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"955_CR122","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/jclinpath-2013-201620","volume":"66","author":"JK Dyson","year":"2013","unstructured":"Dyson, J. K., McPherson, S. & Anstee, Q. M. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J. Clin. Pathol. 66, 1033\u20131045 (2013).","journal-title":"J. Clin. Pathol."},{"key":"955_CR123","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","volume":"57","author":"SA Harrison","year":"2008","unstructured":"Harrison, S. A., Oliver, D., Arnold, H. L., Gogia, S. & Neuschwander-Tetri, B. A. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57, 1441\u20131447 (2008).","journal-title":"Gut"},{"key":"955_CR124","first-page":"518","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai, C. T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518\u2013526 (2003).","journal-title":"Hepatology"},{"key":"955_CR125","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo, P. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45, 846\u2013854 (2007).","journal-title":"Hepatology"},{"key":"955_CR126","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"955_CR127","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","volume":"73","author":"H Hagstr\u00f6m","year":"2020","unstructured":"Hagstr\u00f6m, H., Talb\u00e4ck, M., Andreasson, A., Walldius, G. & Hammar, N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J. Hepatol. 73, 1023\u20131029 (2020).","journal-title":"J. Hepatol."},{"key":"955_CR128","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jhepr.2019.06.004","volume":"1","author":"M Boyle","year":"2019","unstructured":"Boyle, M. et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep. 1, 188\u2013198 (2019).","journal-title":"JHEP Rep."},{"key":"955_CR129","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","volume":"69","author":"SJ Daniels","year":"2019","unstructured":"Daniels, S. J. et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology 69, 1075\u20131086 (2019).","journal-title":"Hepatology"},{"key":"955_CR130","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00447.2014","volume":"308","author":"MA Karsdal","year":"2015","unstructured":"Karsdal, M. A. et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G807\u2013G830 (2015).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"955_CR131","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","volume":"145","author":"P Angulo","year":"2013","unstructured":"Angulo, P. et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145, 782\u2013789 (2013).","journal-title":"Gastroenterology"},{"key":"955_CR132","doi-asserted-by":"crossref","unstructured":"Anstee, Q. M. et al. Non-invasive fibrosis scores as prognostic biomarkers of liver events, cardiovascular events and all-cause mortality in people with obesity and\/or type 2 diabetes in the UK: a longitudinal cohort study. EASL OS025. J. Hepatol. 77 (2022).","DOI":"10.1016\/S0168-8278(22)00471-8"},{"key":"955_CR133","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE M\u00f3zes","year":"2023","unstructured":"M\u00f3zes, F. E. et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol. Hepatol. 8, 704\u2013713 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"955_CR134","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","volume":"73","author":"Y Vali","year":"2020","unstructured":"Vali, Y. et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J. Hepatol. 73, 252\u2013262 (2020).","journal-title":"J. Hepatol."},{"key":"955_CR135","unstructured":"Anstee, Q. M. et al. Change in fibrosis-4 index (FIB4) over time is associated with subsequent risk of liver events, cardiovascular events, and all-cause mortality in patients with obesity and\/or type 2. The Liver Meeting 2022: American Association for the Study of Liver Diseases (AASLD). Abstract 5049 (2022)."},{"key":"955_CR136","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.32594","volume":"77","author":"T Gidener","year":"2023","unstructured":"Gidener, T. et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology 77, 268\u2013274 (2023).","journal-title":"Hepatology"},{"key":"955_CR137","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/hep.21103","volume":"43","author":"AJ Sanyal","year":"2006","unstructured":"Sanyal, A. J. et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43, 682\u2013689 (2006).","journal-title":"Hepatology"},{"key":"955_CR138","unstructured":"Anstee, Q. M. et al. Longitudinal variability of noninvasive tests of fibrosis: implications for treatment response monitoring in patients with NASH. International Liver Congress, 23-26 June 2021, Abstract PO-1568 (2021)."},{"key":"955_CR139","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.231092","volume":"309","author":"K Fowler","year":"2023","unstructured":"Fowler, K. et al. Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: the NIMBLE consortium. Radiology 309, e231092 (2023).","journal-title":"Radiology"},{"key":"955_CR140","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jhep.2021.05.037","volume":"75","author":"DN Rasmussen","year":"2021","unstructured":"Rasmussen, D. N. et al. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J. Hepatol. 75, 1017\u20131025 (2021).","journal-title":"J. Hepatol."},{"key":"955_CR141","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jhep.2022.11.028","volume":"78","author":"DGK Rasmussen","year":"2023","unstructured":"Rasmussen, D. G. K. et al. NAFLD and NASH biomarker qualification in the LITMUS consortium \u2014 lessons learned. J. Hepatol. 78, 852\u2013865 (2023).","journal-title":"J. Hepatol."},{"key":"955_CR142","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis, R. et al. Renewing consensus in portal hypertension. J. Hepatol. 76, 959\u2013974 (2022).","journal-title":"J. Hepatol."},{"key":"955_CR143","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cgh.2022.06.013","volume":"21","author":"G Pennisi","year":"2023","unstructured":"Pennisi, G. et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin. Gastroenterol. Hepatol. 21, 1293\u20131302.e5 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR144","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal, A. J. et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J. Hepatol. 78, 247\u2013259 (2023).","journal-title":"J. Hepatol."},{"key":"955_CR145","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/hep.31576","volume":"73","author":"L Calzadilla-Bertot","year":"2021","unstructured":"Calzadilla-Bertot, L. et al. ABIDE: an accurate predictive model of liver decompensation in patients with nonalcoholic fatty liver-related cirrhosis. Hepatology 73, 2238\u20132250 (2021).","journal-title":"Hepatology"},{"key":"955_CR146","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/hep.28824","volume":"64","author":"JG Abraldes","year":"2016","unstructured":"Abraldes, J. G. et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the \u201cAnticipate\u201d study. Hepatology 64, 2173\u20132184 (2016).","journal-title":"Hepatology"},{"key":"955_CR147","doi-asserted-by":"crossref","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","volume":"116","author":"M Pons","year":"2021","unstructured":"Pons, M. et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am. J. Gastroenterol. 116, 723\u2013732 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"955_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.08.004","author":"M Pons","year":"2023","unstructured":"Pons, M. et al. Point-of-care noninvasive prediction of liver-related events in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2023.08.004 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR149","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1161\/STROKEAHA.111.641456","volume":"43","author":"PMW Bath","year":"2012","unstructured":"Bath, P. M. W. et al. Statistical analysis of the primary outcome in acute stroke trials. Stroke 43, 1171\u20131178 (2012).","journal-title":"Stroke"},{"key":"955_CR150","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/0016-5085(90)91168-6","volume":"99","author":"RJ Groszmann","year":"1990","unstructured":"Groszmann, R. J. et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 99, 1401\u20131407 (1990).","journal-title":"Gastroenterology"},{"key":"955_CR151","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/gast.1996.v111.pm8780575","volume":"111","author":"J Vorobioff","year":"1996","unstructured":"Vorobioff, J. et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 111, 701\u2013709 (1996).","journal-title":"Gastroenterology"},{"key":"955_CR152","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hep.1840110302","volume":"11","author":"F Bendtsen","year":"1990","unstructured":"Bendtsen, F., Skovgaard, L. T., S\u00f8rensen, T. I. & Matzen, P. Agreement among multiple observers on endoscopic diagnosis of esophageal varices before bleeding. Hepatology 11, 341\u2013347 (1990).","journal-title":"Hepatology"},{"key":"955_CR153","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMoa044456","volume":"353","author":"RJ Groszmann","year":"2005","unstructured":"Groszmann, R. J. et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N. Engl. J. Med. 353, 2254\u20132261 (2005).","journal-title":"N. Engl. J. Med."},{"key":"955_CR154","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41575-019-0168-0","volume":"16","author":"IA Rowe","year":"2019","unstructured":"Rowe, I. A. & Parker, R. The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information. Nat. Rev. Gastroenterol. Hepatol. 16, 449\u2013450 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"955_CR155","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group.","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383\u20131389 (1994).","journal-title":"Lancet"},{"key":"955_CR156","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2022.09.021","volume":"78","author":"JM Peric\u00e0s","year":"2023","unstructured":"Peric\u00e0s, J. M. et al. Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. J. Hepatol. 78, 442\u2013447 (2023).","journal-title":"J. Hepatol."},{"key":"955_CR157","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep4.1079","volume":"1","author":"C Filozof","year":"2017","unstructured":"Filozof, C. et al. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: facilitating development approaches for an emerging epidemic. Hepatol. Commun. 1, 577\u2013585 (2017).","journal-title":"Hepatol. Commun."},{"key":"955_CR158","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","volume":"38","author":"P Bedossa","year":"2003","unstructured":"Bedossa, P., Darg\u00e8re, D. & Paradis, V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38, 1449\u2013145 (2003).","journal-title":"Hepatology"},{"key":"955_CR159","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cgh.2022.03.015","volume":"21","author":"JE Shearer","year":"2023","unstructured":"Shearer, J. E., Jones, R., Parker, R., Ferguson, J. & Rowe, I. A. The natural history of advanced chronic liver disease defined by transient elastography. Clin. Gastroenterol. Hepatol. 21, 694\u2013703.e8 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR160","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.16806","volume":"55","author":"JE Shearer","year":"2022","unstructured":"Shearer, J. E. et al. Systematic review: development of a consensus code set to identify cirrhosis in electronic health records. Aliment. Pharmacol. Ther. 55, 645\u2013657 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"955_CR161","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2021.09.030","volume":"76","author":"V Mallet","year":"2022","unstructured":"Mallet, V. et al. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. J. Hepatol. 76, 265\u2013274 (2022).","journal-title":"J. Hepatol."},{"key":"955_CR162","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","volume":"77","author":"K Staufer","year":"2022","unstructured":"Staufer, K. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J. Hepatol. 77, 918\u2013993 (2022).","journal-title":"J. Hepatol."},{"key":"955_CR163","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.31726","volume":"74","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m, H. et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology 74, 474\u2013482 (2021).","journal-title":"Hepatology"},{"key":"955_CR164","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","volume":"59","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther. 59, 51\u201363 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"955_CR165","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/hep.31070","volume":"72","author":"G D\u2019Amico","year":"2020","unstructured":"D\u2019Amico, G., Abraldes, J. G., Rebora, P., Valsecchi, M. G. & Garcia-Tsao, G. Ordinal outcomes are superior to binary outcomes for designing and evaluating clinical trials in compensated cirrhosis. Hepatology 72, 1029\u20131042 (2020).","journal-title":"Hepatology"},{"key":"955_CR166","doi-asserted-by":"crossref","first-page":"100809","DOI":"10.1016\/j.jhepr.2023.100809","volume":"5","author":"G Pennisi","year":"2023","unstructured":"Pennisi, G. et al. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease. JHEP Rep. 5, 100809 (2023).","journal-title":"JHEP Rep."},{"key":"955_CR167","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","volume":"73","author":"SA Harrison","year":"2020","unstructured":"Harrison, S. A. et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J. Hepatol. 73, 26\u201339 (2020).","journal-title":"J. Hepatol."},{"key":"955_CR168","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2020.09.029","volume":"74","author":"C Frenette","year":"2021","unstructured":"Frenette, C. et al. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis. J. Hepatol. 74, 274\u2013282 (2021).","journal-title":"J. Hepatol."},{"key":"955_CR169","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jhep.2019.12.010","volume":"72","author":"G Garcia-Tsao","year":"2020","unstructured":"Garcia-Tsao, G. et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J. Hepatol. 72, 885\u2013895 (2020).","journal-title":"J. Hepatol."},{"key":"955_CR170","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba, R. et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73, 625\u2013643 (2021).","journal-title":"Hepatology"},{"key":"955_CR171","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","volume":"22","author":"MF Abdelmalek","year":"2023","unstructured":"Abdelmalek, M. F. et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): a randomized phase 2b study. Clin. Gastroenterol. Hepatol. 22, 113\u2013123.e9 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"955_CR172","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04267393 (2021)."},{"key":"955_CR173","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05282121 (2022)."},{"key":"955_CR174","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05039450 (2023)."},{"key":"955_CR175","unstructured":"Harrell Jr, F. Harrell miscellaneous. R package version 5.1-1 https:\/\/cran.r-project.org\/web\/packages\/Hmisc\/Hmisc.pdf (2023)."}],"updated-by":[{"DOI":"10.1038\/s41575-024-00976-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000}}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-00955-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-00955-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-00955-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T09:05:13Z","timestamp":1729847113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-024-00955-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":175,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1038\/s41575-024-00955-8","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"3 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41575-024-00976-3","URL":"https:\/\/doi.org\/10.1038\/s41575-024-00976-3","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}